Actively Recruiting
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-cancer Therapies: a Retrospective Cost Research and Prospective Longitudinal Monitoring Study
Led by Chang Gung Memorial Hospital · Updated on 2025-02-27
320
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how patients with cancer respond to COVID-19 vaccination by studying the levels of protective antibodies over time. The focus is on individuals with solid organ malignancies receiving various anti-cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, as well as those who have been disease-free for at least six months. Since cancer patients were excluded from initial vaccine trials, this study seeks to fill knowledge gaps about vaccine safety and effectiveness in this group. Participants include cancer patients who are either undergoing active treatment or are disease-free for six months or more. They are grouped based on their treatment type: chemotherapy, targeted therapy, immunotherapy, or disease-free status. The study involves monitoring antibody trends related to COVID-19 infection and vaccination at multiple time points over a 12-month period. During the study, researchers will collect blood samples to measure neutralizing and spike antibody levels every three months for up to one year. Participants will be followed to track their immune response depending on their cancer treatment and biological aging status. The study will also assess how antibody levels change over time and correlate with different treatments and patient characteristics. Safety and consent are carefully monitored throughout the trial.
CONDITIONS
Brief Title
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 20 years old
- Cancer patients receiving chemotherapy, targeted therapy, or immunotherapy
- Cancer patients who have been disease-free for 6 months or more
- Cancer patients fully vaccinated with any brand of COVID-19 vaccine or unvaccinated patients willing to complete vaccination
- Patients who agree to the informed consent of the study protocol
You will not qualify if you...
- Patients who refuse the protocol of N-antibody test and Out-Patient Departments follow-up
- Patients whom investigators suggest to withdraw
- Patients who choose to withdraw from the trial at any timepoint
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants are observed over time to measure neutralizing antibody levels and other immune responses related to COVID-19, considering their anti-cancer therapies and biological aging.
Periodic visits over 12 months for antibody testing
Trial Site Locations
Total: 1 location
1
TuCheng Hospital
New Taipei City, Taiwan, 23652
Actively Recruiting
Research Team
C
Chia-Hsun Hsieh, PhD
J
Jeng How Yang, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here